research First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.
ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
Search
for
Sort by
Research
510-540 / 1000+ results
research Analysis of hormone antagonists in clinical and municipal wastewater by isotopic dilution liquid chromatography tandem mass spectrometry
Researchers developed a method to detect hormone-blocking drugs in wastewater and found them in Beijing's sewage, suggesting they can survive sewage treatment.
research 709 Nitric oxide-releasing topical therapeutic agent for atopic dermatitis
SB414 may be an effective treatment for atopic dermatitis by reducing swelling and bacterial infection.
research Effectiveness of Abrocitinib in Adolescent Alopecia Areata: A Prospective Observational Pilot Study
Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.
research Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
Cancer treatments often cause skin, nail, and hair problems.
research COMBINATION OF AN ANTIANDROGEN AND A 5α-REDUCTASE INHIBITOR: A FURTHER STEP TOWARDS TOTAL ANDROGEN BLOCKADE?
Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.
research Errata
The document corrects errors in previous articles, including a reversed term, updated subject weights, hair count data, and reference numbering.
research Anti-inflammatory activity of ointments of indomethacin and its calcium salt applied to abdominal skin of rat.
IND-Ca ointment effectively reduces inflammation with minimal skin irritation.
research Alopecia areata: Ritlecitinib generates substantial re-growth of scalp hair
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
research In vitro, ex vivo, and clinical evaluation of anti‐aging gel containing EPA and CBD
The gel with CBD and EPA reduced wrinkles, improved skin hydration and elasticity, and had strong anti-aging effects.
research Interventions for preventing the progression of autosomal dominant polycystic kidney disease
Tolvaptan can slow kidney disease progression, but doesn't affect mortality or kidney failure.
research Treatment of moderate-to-severe alopecia areata in adolescents with baricitinib: A retrospective review of 29 patients
Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.
research Caffeic acid N-[3,5-bis(trifluoromethyl)phenyl] amide as a non-steroidal inhibitor for steroid 5α-reductase type 1 using a human keratinocyte cell-based assay and molecular dynamics
Compound 4 is a promising treatment for hair loss with low toxicity.
research Complications of cataract surgery in Wistar rats undergoing treatment with tamsulosin
Stopping tamsulosin one month before cataract surgery reduces eye surgery complications in rats.
research Efficacy of Tofacitinib in the Treatment of Universal Alopecia Areata and Primary Sjögren Syndrome
Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.
research Dermatologic adverse events in EGFR-TKIs: A real-world analysis.
EGFR-TKIs can cause unexpected skin, nail, and hair issues.
research TRIDAX PROCUMBENS MEDICINE FOR LIFE: AN OVERVIEW
Tridax procumbens is a versatile herb with many health benefits.
research Efficacy of derinat as a treatment for murine and androgenetic alopecia (AGA) patients
Derinat may improve hair growth and quality of life in hair loss patients by reducing oxidative stress.
research Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
Baricitinib is generally safe for long-term use in treating severe alopecia areata.
research Abrocitinib in the Treatment of Severe Alopecia Areata in a Pediatric Patient: A Case Report
Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
research A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes
Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
research Solubilization and Solid‐State Characterization of a Poorly Soluble 5‐α Reductase Inhibitor
GI197111X is best dissolved in Capmul MCM for trials.
research Chaperones as thermodynamic sensors
New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.
research FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
The FDA approved a new Pfizer drug for hair loss in teens.
research UTMD Enhances Targeting of Diclofenac and Doxil® to Boost Tumor Immunotherapy
UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.
research Efficacy and Safety of Ritlecitinib in Alopecia Areata: A Systematic Review and Meta-Analysis (Preprint)
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
research Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
research 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
research Editorial Comment
5-ARI therapy may help prevent prostate cancer progression.